Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), commonly known as Receptor Activator of Nuclear Factor-κB (RANK), is a type I transmembrane protein that plays a pivotal role in bone homeostasis and immune regulation. Upon binding to its cognate ligand, RANKL (TNFSF11), RANK recruits tumor necrosis factor receptor-associated factors (TRAFs) to activate downstream signaling cascades, including the NF-κB, MAPK, and JNK pathways. This signaling axis is the master regulator of osteoclastogenesis, driving the differentiation, activation, and survival of bone-resorbing osteoclasts. Beyond bone remodeling, RANK signaling is involved in T-cell and dendritic cell interactions, lymph node organogenesis, and mammary gland development.
Dysregulation of the RANK/RANKL pathway is implicated in various bone pathologies and malignancies. Overactivation of this pathway leads to excessive bone resorption, contributing to osteoporosis, Paget's disease of bone, and osteolytic bone metastases in cancers such as breast and prostate cancer. Conversely, loss-of-function mutations in TNFRSF11A cause osteoclast-poor autosomal recessive osteopetrosis. In oncology, RANK expression on tumor cells promotes epithelial-mesenchymal transition, migration, and the establishment of a metastatic niche in bone. Therapeutic targeting of this pathway is clinically achieved using denosumab, a monoclonal antibody that binds RANKL to prevent its interaction with RANK, thereby effectively suppressing osteoclast-mediated bone destruction.
Inhibition of the RANKL/RANK signaling pathway. Denosumab is a monoclonal antibody that binds to RANKL (the ligand of RANK), preventing it from binding to and activating the RANK receptor on osteoclast precursors and mature osteoclasts. This blocks downstream NF-κB and MAPK signaling, thereby suppressing osteoclast differentiation, activation, and survival, and reducing bone resorption.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 11A (RANK).